Literature DB >> 24251079

Chemokine-enhanced DNA vaccination in cancer immunotherapy.

Olga Igoucheva1, Rebecca Jonas, Vitali Alexeev.   

Abstract

We have demonstrated that priming of intratumoral and intradermal vaccination sites with chemokines enhances cytotoxic immune response against established neoplasms. Additional insights into the molecular mechanisms that underlie these findings and the optimization of such an approach may lead to the development of cost-effective and generic immunotherapeutic regimens against cancer.

Entities:  

Keywords:  DNA vaccine; chemokines; intradermal vaccination; intratumoral vaccination; leukocyte recruitment; therapeutic vaccine

Year:  2013        PMID： 24251079      PMCID： PMC3827092          DOI： 10.4161/onci.26092

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Ipilimumab.

Authors:  Vernon K Sondak; Keiran S M Smalley; Ragini Kudchadkar; Seden Grippon; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

2.  CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.

Authors:  Jae Yeo Park; Dong-Hoon Jin; Chang-Min Lee; Min Ja Jang; Sun Young Lee; Hyo Seon Shin; Yoon Hee Chung; Kyung Yong Kim; Sung Su Kim; Won Bok Lee; Yong Kyoo Shin; Wang Jae Lee; Yeong-Min Park; Daejin Kim
Journal:  J Immunother       Date:  2010-06       Impact factor: 4.456

3.  The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells.

Authors:  Kenneth Flanagan; Dorota Moroziewicz; Heesun Kwak; Heidi Hörig; Howard L Kaufman
Journal:  Cell Immunol       Date:  2005-01-21       Impact factor: 4.868

4.  Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication.

Authors:  Laura Novak; Olga Igoucheva; Stephanie Cho; Vitali Alexeev
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

5.  CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles.

Authors:  Keely G McDonald; Jacquelyn S McDonough; Caihong Wang; Torsten Kucharzik; Ifor R Williams; Rodney D Newberry
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

6.  Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza.

Authors:  Javier Rangel-Moreno; Juan E Moyron-Quiroz; Louise Hartson; Kim Kusser; Troy D Randall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

7.  Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.

Authors:  O Igoucheva; M Grazzini; A Pidich; D M Kemp; M Larijani; M Farber; J Lorton; U Rodeck; V Alexeev
Journal:  Gene Ther       Date:  2013-04-04       Impact factor: 5.250

Review 8.  Immunotherapeutic strategies for the treatment of malignant melanoma.

Authors:  V Alexeev; T Mucci; O Igoucheva
Journal:  G Ital Dermatol Venereol       Date:  2008-04       Impact factor: 2.011

9.  Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.

Authors:  A Wu; Q Zeng; T H Kang; S Peng; E Roosinovich; S I Pai; C-F Hung
Journal:  Gene Ther       Date:  2010-10-28       Impact factor: 5.250
  9 in total
  2 in total

1.  CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.

Authors:  T Nguyen-Hoai; M Pham-Duc; M Gries; B Dörken; A Pezzutto; J Westermann
Journal:  Cancer Gene Ther       Date:  2016-04-08       Impact factor: 5.987

Review 2.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.